Literature DB >> 24790861

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization.

Halil Ibrahim Onder1, Mesut Erdurmus2, Yasin Yücel Bucak3, Hüseyin Simavli3, Murat Oktay4, Ahmet Sahap Kukner2.   

Abstract

AIM: To evaluate the inhibitory effects of regorafenib (BAY 73-4506), a multikinase inhibitor, on corneal neovascularization (NV).
METHODS: Thirty adult male Sprague-Dawley rats weighing 250-300 g, were used. Corneal NV was induced by NaOH in the left eyes of each rat. Following the establishment of alkali burn, the animals were randomized into five groups according to topical treatment. Group 1 (n = 6) received 0.9% NaCl, Group 2 (n = 6) received dimethyl sulfoxide, Group 3 (n = 6) received regorafenib 1 mg/mL, Group 4 (n =6) received bevacizumab 5 mg/mL and Group 5 (n = 6) received 0.1% dexamethasone phosphate. On the 7d, the corneal surface covered with neovascular vessels was measured on photographs as the percentage of the cornea's total area using computer-imaging analysis. The corneas obtained from rats were semiquantitatively evaluated for caspase-3 and vascular endothelial growth factor by immunostaining.
RESULTS: A statistically significant difference in the percent area of corneal NV was found among the groups (P <0.001). Although the Group 5 had the smallest percent area of corneal NV, there was no difference among Groups 3, 4 and 5 (P >0.005). There was a statistically significant difference among the groups in apoptotic cell density (P = 0.002). The staining intensity of vascular endothelial growth factor in the epithelial and endothelial layers of cornea was significantly different among the groups (P <0.05). The staining intensity of epithelial and endothelial vascular endothelial growth factor was significantly weaker in Groups 3, 4 and 5 than in Groups 1 and 2.
CONCLUSION: Topical administration of regorafenib 1 mg/mL is partly effective for preventing alkali-induced corneal NV in rats.

Entities:  

Keywords:  corneal neovascularization; regorafenib; tyrosine kinase inhibitor

Year:  2014        PMID: 24790861      PMCID: PMC4003073          DOI: 10.3980/j.issn.2222-3959.2014.02.06

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  33 in total

Review 1.  Treatments for corneal neovascularization: a review.

Authors:  Deepak Gupta; Chris Illingworth
Journal:  Cornea       Date:  2011-08       Impact factor: 2.651

2.  Inhibitory effect of triamcinolone acetonide on corneal neovascularization.

Authors:  Masatoshi Murata; Shinji Shimizu; Saburo Horiuchi; Masayuki Taira
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-26       Impact factor: 3.117

3.  Antioxidant activity of Nigella sativa essential oil.

Authors:  M Burits; F Bucar
Journal:  Phytother Res       Date:  2000-08       Impact factor: 5.878

4.  Inhibition of corneal angiogenesis by ascorbic acid in the rat model.

Authors:  Gholam A Peyman; Muhamet Kivilcim; Ana Munoz Morales; John T DellaCroce; Mandi D Conway
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-21       Impact factor: 3.117

5.  Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.

Authors:  Marisol R Castro; David Lutz; Jeffrey L Edelman
Journal:  Exp Eye Res       Date:  2004-08       Impact factor: 3.467

6.  Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis.

Authors:  Liang Dan; Yan Shi-long; Lin Miao-li; Li Yong-ping; Ma Hong-jie; Zhang Ying; Wang Xiang-gui
Journal:  Curr Eye Res       Date:  2008-08       Impact factor: 2.424

7.  Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.

Authors:  Kamarul Zaki; Shahzeena Aslam; Tim Eisen
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

8.  Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer.

Authors:  Baris Sonmez; Umit Beden; Dilek Erkan
Journal:  Int Ophthalmol       Date:  2007-12-20       Impact factor: 2.031

9.  Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.

Authors:  Georg Gerten
Journal:  Cornea       Date:  2008-12       Impact factor: 2.651

10.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Authors:  Felix Bock; Yanyan König; Friedrich Kruse; Martin Baier; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-13       Impact factor: 3.117

View more
  6 in total

Review 1.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

Review 2.  Current and Upcoming Therapies for Ocular Surface Chemical Injuries.

Authors:  Alireza Baradaran-Rafii; Medi Eslani; Zeeshan Haq; Ebrahim Shirzadeh; Michael J Huvard; Ali R Djalilian
Journal:  Ocul Surf       Date:  2016-09-17       Impact factor: 5.033

3.  Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization.

Authors:  Jung Eun Lee; Koung Li Kim; Danbi Kim; Yeongju Yeo; Hyounkoo Han; Myung Goo Kim; Sun Hwa Kim; Hyuncheol Kim; Ji Hoon Jeong; Wonhee Suh
Journal:  Int J Nanomedicine       Date:  2017-07-05

Review 4.  Therapeutic approaches for corneal neovascularization.

Authors:  Sepehr Feizi; Amir A Azari; Sharareh Safapour
Journal:  Eye Vis (Lond)       Date:  2017-12-10

Review 5.  Corneal neovascularization and biological therapy.

Authors:  O B Voiculescu; L M Voinea; C Alexandrescu
Journal:  J Med Life       Date:  2015 Oct-Dec

Review 6.  Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.

Authors:  Zachary Barry; Bomina Park; Timothy W Corson
Journal:  Molecules       Date:  2020-07-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.